Targeting cell cycle kinases and kinesins in anticancer drug development

Expert Opinion on Drug Discovery

Volumn 2, Issue 4, 2007, Pages 539-560

  Yap, Timothy A ^a,b   Molife, L Rhoda ^a   Blagden, Sarah P ^c   de Bono, Johann S ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Aurora kinase; Cell cycle; Checkpoint inhibitors; Cyclin dependent kinase; Mitotic kinesins; Polo like kinase

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BUTYROLACTONE; CARBOPLATIN; CELL CYCLE PROTEIN; CHECKPOINT KINASE 1; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; DOCETAXEL; FLAVOPIRIDOL; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; INDIRUBIN; INDISULAM; IRINOTECAN; KINESIN; MITOXANTRONE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PACLITAXEL; PAULLONE DERIVATIVE; PD 0332991; PHOSPHOTRANSFERASE; ROSCOVITINE; STAUROSPORINE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZK 304709;

ABDOMINAL PAIN; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; BONE MARROW SUPPRESSION; CANCER INHIBITION; CANCER PAIN; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CANCER; COLON ULCER; CONCENTRATION RESPONSE; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; FATIGUE; FOLLICULITIS; GASTROINTESTINAL TOXICITY; GLIOMA; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY CARCINOMA; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LYMPHOMA; MELANOMA; METABOLIC DISORDER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; REVIEW; SEPSIS; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

EID: 34447503273     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.4.539     Document Type: Review

References (217)

1. HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57-70.
2. SAUSVILLE EA: Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med. (2002) 8:S32-37.
3. BLAGDEN S, DE BONO J: Drugging cell cycle kinases in cancer therapy. Curr. Drug Targets (2005) 6:325-335.
4. BAI C, RICHMAN R, ELLEDGE SJ: HUMAN cyclin F. EMBO J. (1994) 13:6087-6098.
5. KONG M, BARNES EA, OLLENDORFF V, DONOGHUE DJ: Cyclin F regulates the nuclear localization of cyclin B1 through a cyclin-cyclin interaction. Embo. J. (2000) 19:1378-1388.
6. NURSE P: Genetic control of cell size at cell division in yeast. Nature (1975) 256:547-551.
7. MASUI Y, MARKERT CL: Cytoplasmic control of nuclear behavior during meiotic maturation of frog oocytes. J. Exp. Zool. (1971) 177:129-145.
8. SMITH LD, ECKER RE: The interaction of steroids with rana pipiens oocytes in the induction of maturation. Dev. Biol. (1971) 25:232-247.
9. LOHKA MJ, MASUI Y: Formation in vitro of sperm pronuclei and mitotic chromosomes induced by amphibian ooplasmic components. Science (1983) 220:719-721.
10. LUNDBERG AS, WEINBERG RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell Biol. (1998) 18:753-761.
11. HARBOUR JW, LUO RX, DEI SANTI A et al.: CDK phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell (1999) 98:859-869.
12. SHERR CJ: G1 phase progression: cycling on cue. Cell (1994) 79:551-555.
13. PINES J: Cyclins: wheels within wheels. Cell Growth Differ. (1991) 2:305-310.
14. SHERR CJ, ROBERTS JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. (1995) 9:1149-1163.
15. HARPER JW, ELLEDGE SJ: The role of Cdk7 in CAK function, a retro-retrospective. Genes Dev. (1998) 12:285-289.
16. KALDIS P, SOLOMON MJ: Analysis of CAK activities from human cells. Eur. J. Biochem. (2000) 267:4213-4221.
17. COLEMAN TR, DUNPHY WG: Cdc2 regulatory factors. Curr. Opin. Cell Biol. (1994) 6:877-882.
18. MEINHART A, KAMENSKI T, HOEPPNER S et al.: A structural perspective of CTD function. Genes Dev. (2005) 19:1401-1415.
19. PRELICH G: RNA polymerase II carboxy-terminal domain kinases: emerging clues to their function. Eukaryot. Cell (2002) 1:153-162.
20. YAMAMOTO H, MONDEN T, MIYOSHI H et al.: Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells. Int. J. Oncol. (1998) 13:233-239.
21. DOBASHI Y, SHOJI M, JIANG SX et al.: Active cyclin A-Cdk2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am. J. Pathol. (1998) 153:963-972.
22. ORTEGA S, PRIETO I, ODAJIMA J et al.: Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. (2003) 35:25-31.
23. TETSU O, MCCORMICK F: Proliferation of cancer cells despite Cdk2 inhibition. Cancer Cell (2003) 3:233-245.
24. COLLINS VP: Gene amplification in human gliomas. Glia. (1995) 15:289-296.
25. REIFENBERGER G, REIFENBERGER J, ICHIMURA K et al.: Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of Cdk4, SAS, and MDM2. Cancer Res (1994) 54:4299-4303.
26. AN HX, BECKMANN MW, REIFENBERGER G et al.: Gene amplification and overexpression of Cdk4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am. J. Pathol. (1999) 154:113-118.
27. WIKMAN H, NYMARK P, VAYRYNEN A et al.: Cdk4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. Genes Chrom. Can. (2005) 42:193-199.
28. FORUS A, LARRAMENDY ML, MEZA-ZEPEDA LA et al.: Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases. Cancer Genet. Cytogenet. (2001) 125:100-111.
29. KHATIB ZA, MATSUSHIME H, VALENTINE M et al.: Coamplification of the Cdk4 gene with MDM2 and GLI in human sarcomas. Cancer Res. (1993) 53:5535-5541.
30. YU Q, GENG Y, SICINSKI P: Specific protection against breast cancers by cyclin D1 ablation. Nature (2001) 411:1017-1021.
31. YANG C, IONESCU-TIBA V, BURNS K et al.: The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer. Am. J. Pathol. (2004) 164:1031-1038.
32. LANDIS MW, PAWLYK BS, LI T et al.: Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell (2006) 9:13-22.
33. YU Q, SICINSKA E, GENG Y et al.: Requirement for Cdk4 kinase function in breast cancer. Cancer Cell (2006) 9:23-32.
34. SENDEROWICZ AM: Small-molecule cyclin-dependent kinase modulators. Oncogene (2003) 22:6609-6620.
35. SENDEROWICZ AM, SAUSVILLE EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. (2000) 92:376-387.
36. CARLSON B, LAHUSEN T, SINGH S et al.: Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. (1999) 59:4634-4641.
37. PATEL V, SENDEROWICZ AM, PINTO D Jr: et al.: Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Invest. (1998) 102:1674-1681.
38. NEWCOMB EW: Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs (2004) 15:411-419.
39. WANG Q, FAN S, EASTMAN A et al.: UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. (1996) 88:956-965.
40. BUSBY EC, LEISTRITZ DF, ABRAHAM RT et al.: The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res. (2000) 60:2108-2112.
41. YU Q, LA ROSE J, ZHANG H et al.: UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res (2002) 62:5743-5748.
42. SATO S, FUJITA N, TSURUO T: Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene (2002) 21:1727-1738.
43. HOTTE SJ, OZA A, WINQUIST EW et al.: Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann. Oncol. (2006) 17:334-340.
44. OZAWA Y, SUGI NH, NAGASU T et al.: E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur. J. Cancer (2001) 37:2275-2282.
45. WHITTAKER SR, WALTON MI, GARRETT MD, WORKMAN P: The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res. (2004) 64:262-272.
46. MCCLUE SJ, BLAKE D, CLARKE R et al.: In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer (2002) 102:463-468.
47. GOODYEAR S, SHARMA MC: Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein Cdk5. Exp. Mol. Pathol. (2006) 82(1):25-32.
48. RAYNAUD FI, WHITTAKER SR, FISCHER PM et al.: In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin. Cancer Res. (2005) 11:4875-4887.
49. WESIERSKA-GADEK J, GUEORGUIEVA M, HORKY M: Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol. Cancer Ther. (2005) 4:113-124.
50. WESIERSKA-GADEK J, SCHMITZ ML, RANFTLER C: Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells. J. Cell Biochem. (2007) 100:865-874.
51. MISRA RN, XIAO HY, KIM KS et al.: N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5- [5-(1,1-dimethylethyl)-2-oxazolyl]m ethyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem. (2004) 47:1719-1728.
52. SIEMEISTER G, LUECKING U, WAGNER C et al.: Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth Inhibitor ZK-304709. Biomed. Pharmacother. (2006) 60:269-272.
53. TOOGOOD PL, HARVEY PJ, REPINE JT et al.: Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J. Med. Chem. (2005) 48:2388-2406.
54. SHAPIRO GI: CYCLIN-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. (2006) 24:1770-1783.
55. FRY DW, HARVEY PJ, KELLER PR et al.: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. (2004) 3:1427-1438.
56. SENDEROWICZ AM, HEADLEE D, STINSON SF et al.: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. (1998) 16:2986-2999.
57. THOMAS JP, TUTSCH KD, CLEARY JF et al.: Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother. Pharmacol. (2002) 50:465-472.
58. STADLER WM, VOGELZANG NJ, AMATO R et al.: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J. Clin. Oncol. (2000) 18:371-375.
59. SCHWARTZ GK, ILSON D, SALTZ L et al.: Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol. (2001) 19:1985-1992.
60. SHAPIRO GI, SUPKO JG, PATTERSON A et al.: A Phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage i.v. non-small cell lung cancer. Clin Cancer Res (2001) 7:1590-1599.
61. LIN TS, HOWARD OM, NEUBERG DS et al.: Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk. Lymphoma (2002) 43:793-797.
62. AKLILU M, KINDLER HL, DONEHOWER RC et al.: Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann. Oncol. (2003) 14:1270-1273.
63. LIU G, GANDARA DR, LARA PN Jr et al.: A Phase II trial of flavopiridol (NSC 649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin. Cancer Res. (2004) 10:924-928.
64. FLINN IW, BYRD JC, BARTLETT N et al.: Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk. Res. (2005) 29:1253-1257.
65. BYRD JC, PETERSON BL, GABRILOVE J et al.: Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin. Cancer Res. (2005) 11:4176-4181.
66. TAN AR, HEADLEE D, MESSMANN R et al.: Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J. Clin. Oncol. (2002) 20:4074-4082.
67. ARGUELLO F, ALEXANDER M, STERRY JA et al.: Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood (1998) 91:2482-2490.
68. SASAKI Y, SASAKI T, MINAMI H et al.: A Phase I pharmacokinetic (PK)-pharmacodynamic (PD) study of flavopiridol by 24 hours continuous infusion (CI) repeating every week. Proc. Am. Soc. Clin. Oncol. 21:(2002) (abstr 371).
69. KOUROUKIS CT, BELCH A, CRUMP M et al.: Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a Phase II study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (2003) 21:1740-1745.
70. BURDETTE-RADOUX S, TOZER RG, LOHMANN RC et al.: Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest. New Drugs (2004) 22:315-322.
71. GRENDYS EC Jr, BLESSING JA, BURGER R, HOFFMAN J: A Phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. (2005) 98:249-253.
72. Van VELDHUIZEN PJ, FAULKENER JR, LARA P Jr et al.: A Phase II study of flavopridol in patients with advanced renal cell carcinoma: results of Southwest oncology group trial 0109. Can. Chemother. Pharmacol. (2005)56:39-45.
73. DISPENZIERI A, GERTZ MA, LACY MQ et al.: Flavopiridol in patients with relapsed or refractory multiple myeloma: a Phase 2 trial with clinical and pharmacodynamic end-points. Haematol. (2006) 91:390-393.
74. MATRANGA CB, SHAPIRO GI: Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res. (2002) 62:1707-1717.
75. MOTWANI M, DELOHERY TM, SCHWARTZ GK: Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res. (1999) 5:1876-1883.
76. MOTWANI M, RIZZO C, SIROTNAK F et al.: Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol. Cancer Ther. (2003) 2:549-555.
77. JUNG CP, MOTWANI MV, SCHWARTZ GK: Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin. Cancer Res. (2001) 7:2527-2536.
78. SCHWARTZ GK, O'REILLY E, ILSON D et al.: Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J. Clin. Oncol. (2002) 20:2157-2170.
79. TAN AR, YANG X, BERMAN A et al.: Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin. Cancer Res. (2004) 10:5038-5047.
80. SHAH MA, KORTMANSKY J, MOTWANI M et al.: A Phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin. Cancer Res. (2005) 11:3836-3845.
81. BIBLE KC, LENSING JL, NELSON SA et al.: Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin. Cancer Res. (2005) 11:5935-5941.
82. KARP JE, PASSANITI A, GOJO I et al.: Phase I and pharmacokinetic study of flavopiridol followed by 1-β-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin. Cancer Res. (2005) 11:8403-8412.
83. SAUSVILLE EA, ARBUCK SG, MESSMANN R et al.: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol. (2001) 19:2319-2333.
84. TAMURA T, SASAKI Y, MINAMI H et al.: Phase I study of UCN-01 by 3-hour infusion (Meeting abstract 611). In: ASCO Annual Meeting. (1999).
85. DEES EC, BAKER SD, O'REILLY S et al.: A Phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin. Cancer Res. (2005) 11:664-671.
86. POLLACK IF, KAWECKI S, LAZO JS: Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J. Neurosurg. (1996) 84:1024-1032.
87. HSUEH CT, KELSEN D, SCHWARTZ GK: UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin. Cancer Res. (1998) 4:2201-2206.
88. KORTMANSKY J, SHAH MA, KAUBISCH A et al.: Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors. J. Clin. Oncol. (2005) 23:1875-1884.
89. LARA PN, Jr:, MACK PC, SYNOLD T et al.: The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium Phase I pharmacokinetic and molecular correlative trial. Clin. Cancer Res. (2005) 11:4444-4450.
90. RINI BI, WEINBERG V, SHAW V et al.: Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer (2004) 101:90-95.
91. PUNT CJ, FUMOLEAU P, VAN DE WALLE B et al.: Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann. Oncol. (2001) 12:1289-1293.
92. RAYMOND E, TEN BOKKEL HUININK WW, TAIEB J et al.: Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. J. Clin. Oncol. (2002) 20:3508-3521.
93. TERRET C, ZANETTA S, ROCHE H et al.: Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). Eur. J. Cancer (2003) 39:1097-1104.
94. DITTRICH C, DUMEZ H, CALVERT H et al.: Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin. Cancer Res. (2003) 9:5195-5204.
95. DROZ JP: Phase I trial of five-days continuous infusion E7070 N-(3-chloro-7-indolyl)-1,4-benzenedisulfo namide] in patients with solid tumors. Proc. American Association of Cancer Res. (2000) 41:609.
96. HADDAD RI, WEINSTEIN LJ, WIECZOREK TJ et al.: A Phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblasmma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin. Cancer Res. (2004) 10:4680-4687.
97. SMYTH JF, AAMDAL S, AWADA A et al.: Phase II study of E7070 in patients with metastatic melanoma. Ann. Oncol. (2005) 16:158-161.
98. MAINWARING PN, VAN CUTSEM E, VAN LAETHEM J et al.: A multicentre randomised Phase II study of E7070 in patients with colorectal cancer who have failed 5-fluorouracil-based chemotherapy. In ASCO Annual Meeting (Abstract 611), Edition (2002).
99. TALBOT D, NORBURY C, SLADE M et al.: A Phase II and pharmacodynamic study of E7070 in patients with non-small cell lung cancer (NSCLC) who have failed platinum-based chemotherapy. In: ASCO Annual Meeting (Abstract 1306), Edition (2002).
100. PIERGA J, FAIVRE S, VERA K et al.: A Phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients (pts) with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:abstr 840
101. BENSON C, WHITE J, TWELVES C et al.: A Phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy. Proc. Am. Soc. Clin. Oncol. (2003) 22: abstr 838.
102. WHITE JD, CASSIDY J, TWELVES C et al.: A Phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy. Journal of Clinical Oncology, (2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol. 22, No 14S (July 15 Supplement), (2004) 3042.
103. MACCALLUM DE, MELVILLE J, FRAME S et al.: Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. (2005) 65:5399-5407.
104. RAJE N, KUMAR S, HIDESHIMA T et al.: Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood (2005) 106:1042-1047.
105. ALVI AJ, AUSTEN B, WESTON VJ et al.: A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood (2005) 105:4484-4491.
106. LACRIMA K, VALENTINI A, LAMBERTINI C et al.: In vitro activity of cyclin-dependent kinase inhibitor CYC202 (seliciclib, R-roscovitine) in mantle cell lymphomas. Ann. Oncol. (2005) 16 :1169-1176.
107. SIEGEL-LAKHAI WS, RODENSTEIN DO, BEIJNEN JH et al.: Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol. ASCO Annual Meeting Proceedings. (2005) 23(16 Suppl.):2060.
108. JONES SF, BURRIS HA, KIES M et al.: A Phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 798.
109. MCCORMICk J, GADGEEL SM, HELMKE W et al.: Phase I study of BMS-387032, a cyclin dependent kinase (CDK) 2 inhibitor. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 835.
110. SHAPIRO G, LEWIS N, BAI S et al.: A Phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 with a 24-hr infusion given every three weeks in patients with metastatic refractory solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 799.
111. GRAHAM J, WAGNER K, PLUMMER R et al.: Phase I dose-escalation study of novel oral multi-target tumor growth inhibitor (MTGI) ZK 304709 administered daily for 7 days of a 21-day cycle to patients with advanced solid tumors. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):2073.
112. AHMED S, MOLIFE R, SHAW H et al.: Phase I dose-escalation study of ZK 304709, an oral multi-target tumor growth inhibitor (MTGI), administered for 14 days of a 28-day cycle. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):2076.
113. SAUSVILLE EA: Aurora kinases dawn as cancer drug targets. Nat. Med. (2004) 10:234-235.
114. CARMENA M, EARNSHAW WC: The cellular geography of aurora kinases. Nat. Rev. Mol. Cell Biol. (2003) 4:842-854.
115. KUFER TA, NIGG EA, SILLJE HH: Regulation of aurora-A kinase on the mitotic spindle. Chromosoma (2003) 112:159-163.
116. WALTER AO, SEGHEZZI W, KORVER W et al.: The mitotic serine/ threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene (2000) 19:4906-4916.
117. MATTHEWS N, VISINTIN C, HARTZOULAKIS B et al.: Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expt. Rev. Anticancer Ther. (2006) 6:109-120.
118. KEEN N, TAYLOR S: Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer (2004) 4:927-936.
119. VAGNARELLI P, EARNSHAW WC: Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma (2004) 113:211-222.
120. GASSMANN R, CARVALHO A, HENZING AJ et al.: Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. J. Cell Biol. (2004) 166:179-191.
121. SASAI K, KATAYAMA H, STENOIEN DL et al.: Aurora-C kinase is a novel chromosomal passenger protein that can complement aurora-B kinase function in mitotic cells. Cell Motil. Cytoskeleton (2004) 59:249-263.
122. LI X, SAKASHITA G, MATSUZAKI H et al.: Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, aurora-C. J. Biol. Chem. (2004) 279:47201-47211.
123. LANDEN CN, IMMANENI A, DEAVERS MT et al.: Overexpression of the centrosomal protein aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 23(16 Suppl.):5039.
124. SEN S, ZHOU H, WHITE RA: A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene (1997) 14:2195-2200.
125. SAKAKURA C, HAGIWARA A, YASUOKA R et al.: Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br. J. Cancer (2001) 84:824-831.
126. SEN S, ZHOU H, ZHANG RD et al.: Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J. Natl. Cancer Inst. (2002) 94:1320-1329.
127. BISCHOFF JR, ANDERSON L, ZHU Y et al.: A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. (1998) 17:3052-3065.
128. ZHOU H, KUANG J, ZHONG L et al.: Tumour amplified kinase STK15/ BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. (1998) 20:189-193.
129. TATSUKA M, SATO S, KITAJIMA S et al.: Overexpression of aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene (2005) 24:1122-1127.
130. ARAKI K, NOZAKI K, UEBA T et al.: High expression of aurora-B/ aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas. J. Neurooncol. (2004) 67:53-64.
131. CHIEFFI P, TRONCONE G, CALEO A et al.: Aurora B expression in normal testis and seminomas. J. Endocrinol. (2004) 181:263-270.
132. SORRENTINO R, LIBERTINI S, PALLANTE PL et al.: Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J. Clin. Endocrinol. Metab. (2005) 90:928-935.
133. KATAYAMA H, OTA T, JISAKI F et al.: Mitotic kinase expression and colorectal cancer progression. J. Natl. Cancer Inst. (1999) 91:1160-1162.
134. NAIR JS, TSE A, KEEN N, GK S: A novel aurora B kinase inhibitor with potent anticancer activity either as a single agent or in combination with chemotherapy. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 22(14 Suppl.):9568.
135. BERNARD M, SANSEAU P, HENRY C et al.: Cloning of STK13, a third human protein kinase related to Drosophila aurora and budding yeast Ipll that maps on chromosome 19q13.3-ter. Genomics (1998) 53:406-409.
136. TSENG TC, CHEN SH, HSU YP, TANG TK: Protein kinase profile of sperm and eggs: cloning and characterization of two novel testis-specific protein kinases (AIE1, AIE2) related to yeast and fly chromosome segregation regulators. DNA Cell Biol. (1998) 17:823-833.
137. KIMURA M, MATSUDA Y, YOSHIOKA T, OKANO Y: Cell cycle-dependent expression and centrosome localization of a third human aurora/ Ipll-related protein kinase, AIK3. J. Biol. Chem. (1999) 274:7334-7340.
138. TAKAHASHI T, FUTAMURA M, YOSHIMI N et al.: Centrosomal kinases, HsAIRK1 and HsAIRK3, are overexpressed in primary colorectal cancers. Jpn. J. Cancer Res. (2000) 91:1007-1014.
139. RUBIN EH, SHAPIRO GI, STEIN MN et al.: A Phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):3009.
140. SCHELLENS JH, BOSS D, WITTEVEEN PO et al.: Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):3008.
141. SUNKEL CE, GLOVER DM: Polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J. Cell Sci. (1988) 89(Pt 1):25-38.
142. FENTON B, GLOVER DM: A conserved mitotic kinase active at late anaphase-telophase in syncytial Drosophila embryos. Nature (1993) 363:637-640.
143. GLOVER DM, HAGAN IM, TAVARES AA: Polo-like kinases: a team that plays throughout mitosis. Genes Dev. (1998) 12:3777-3787.
144. STREBHARDT K, ULLRICH A: Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer (2006) 6:321-330.
145. WARNKE S, KEMMLER S, HAMES RS et al.: Polo-like kinase-2 is required for centriole duplication in mammalian cells. Curr. Biol. (2004)14:1200-1207.
146. CONN CW, HENNIGAN RF, DAI W et al.: Incomplete cytokinesis and induction of apoptosis by overexpression of the mammalian polo-like kinase, Plk3. Cancer Res. (2000) 60:6826-6831.
147. KO MA, ROSARIO CO, HUDSON JW et al.: Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat. Genet. (2005) 37:883-888.
148. BETTENCOURT-DIAS M, RODRIGUES-MARTINS A, CARPENTER L et al.: SAK/ PLK4 is required for centriole duplication and flagella development. Curr. Biol. (2005) 15:2199-2207.
149. ECKERDT F, YUAN J, STREBHARDT K: Polo-like kinases and oncogenesis. Oncogene (2005) 24:267-276.
150. TAKAI N, MIYAZAKI T, FUJISAWA K et al.: Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett. (2001) 164:41-49.
151. TAKAI N, MIYAZAKI T, FUJISAWA K et al.: Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett (2001) 169:41-49.
152. WOLF G, ELEZ R, DOERMER A et al.: Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene (1997) 14:543-549.
153. KNECHT R, ELEZ R, OECHLER M et al.: Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. (1999) 59:2794-2797.
154. GRAY PJ Jr, BEARSS DJ, HAN H et al.: Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol. Cancer Ther. (2004) 3:641-646.
155. MUNDT KE, GOLSTEYN RM, LANE HA, NIGG EA: On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression. Biochem. Biophys. Res. Commun. (1997) 239:377-385.
156. JANG YJ, LIN CY, MA S, ERIKSON RL: Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc. Natl. Acad. Sci. USA (2002) 99:1984-1989.
157. SMITS VA, KLOMPMAKER R, ARNAUD L et al.: Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat. Cell Biol. (2000) 2:672-676.
158. VAN VUGT MA, BRAS A, MEDEMA RH: Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol. Cell. (2004) 15:799-811.
159. VAN VUGT MA, BRAS A, MEDEMA RH: Restarting the cell cycle when the checkpoint comes to a halt. Cancer Res. (2005) 65:7037-7040.
160. ANDO K, OZAKI T, YAMAMOTO H et al.: Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J. Biol. Chem. (2004) 279:25549-25561.
161. LI B, OUYANG B, PAN H et al.: Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas. J. Biol. Chem. (1996) 271:19402-19408.
162. DAI W, LI Y, OUYANG B et al.: PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer. Genes Chrom. Can. (2000) 27:332-336.
163. DAI W, LIU T, WANG Q et al.: Down-regulation of PLK3 gene expression by types and amount of dietary fat in rat colon tumors. Int. J. Oncol. (2002) 20:121-126.
164. MUNZERT G, STEINBILD S, FROST A et al.: A Phase I study of two administration schedules of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):3069.
165. HOFHEINZ R, HOCHHAUS A, AL-BATRAN S et al.: A Phase I repeated dose escalation study of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumours. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):2038.
166. PATNAIK A, FORERO L, GOETZ A et al.: HMN-214, a novel oral antimicrotubular agent and inhibitor of polo-like- and cyclin-dependent kinases: clinical, pharmacokinetic (PK) and pharmacodynamic (PD) relationships observed in a Phase I trial of a daily x 5 schedule every 28 days. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 514.
167. GARLAND LL, TAYLOR C, PILKINGTON DL et al.: A Phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin. Cancer Res. (2006) 12:5182-5189.
168. OHNUMA T, CHO SY, ROBOZ J et al.: Phase I study of ON 01910.Na by 3-day continuous infusion (CI) in patients (pts) with advanced cancer. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):13137.
169. DONEHOWER RC, JIMENO A, LI J et al.: Phase I study of ON-01910.Na, a novel cell cycle inhibitor in adult patients with solid tumors. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):13026.
170. WILSON L, JORDAN MA: New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies. J. Chemother. (2004) 16(Suppl. 4):83-85.
171. HAGIWARA H, SUNADA Y: Mechanism of taxane neurotoxicity. Breast Cancer (2004) 11:82-85.
172. WOOD KW, CORNWELL WD, JACKSON JR: Past and future of the mitotic spindle as an oncology target. Curr. Opin. Pharmacol. (2001) 1:370-377.
173. SAKOWICZ R, FINER JT, BERAUD C et al.: Antitumor activity of a kinesin inhibitor. Cancer Res. (2004) 64:3276-3280.
174. BLANGY A, LANE HA, D'HERIN P et al.: Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell (1995) 83:1159-1169.
175. COCHRAN JC, GATIAL JE 3rd, KAPOOR TM, GILBERT SP: Monastrol inhibition of the mitotic kinesin Eg5. J. Biol. Chem (2005) 280:12658-12667.
176. MARCUS AI, PETERS U, THOMAS SL et al.: Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J. Biol. Chem. (2005) 280:11569-11577.
177. WOOD KW, SAKOWICZ R, GOLDSTEIN LS, CLEVELAND DW: CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment. Cell (1997) 91:357-366.
178. MAO Y, ABRIEU A, CLEVELAND DW: Activating and silencing the mitotic checkpoint through CENP-E-dependent activation/inactivation of BubR1. Cell (2003) 114:87-98.
179. MCEWEN BF, CHAN GK, ZUBROWSKI B et al.: CENP-E is essential for reliable bioriented spindle attachment, but chromosome alignment can be achieved via redundant mechanisms in mammalian cells. Mol. Biol. Cell (2001) 12:2776-2789.
180. YAO X, ABRIEU A, ZHENG Y et al.: CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nat. Cell Biol. (2000) 2:484-491.
181. PUTKEY FR, CRAMER T, MORPHEW MK et al.: Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev. Cell. (2002) 3:351-365.
182. DE BONO JS, TA EK: Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. Seminars in oncology (2003) 30:79-92.
183. TAO W, SOUTH VJ, ZHANG Y et al.: Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell (2005) 8:49-59.
184. Clinical investigator's brochure for SB-715992 (GlaxoSmithKline Group Company): In Edition.
185. DAVIS DA, SARKAR SH, HUSSAIN M et al.: Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer (2006) 6:22.
186. JONES SF, PLUMMER ER, BURRIS HA et al.: Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):2027.
187. BURRIS HA, LORUSSO P, JONES S et al.: Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 i.v days 1, 8, 15 q 28 days. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):2004.
188. CHU QS, HOLEN KD, ROWINSKY EK et al.: Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 i.v Q 21 days. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):2078.
189. HEATH EI, ALOUSI A, EDER JP et al.: A Phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):2026.
190. BLAGDEN S, SEEBARAN A, MOLIFE R et al.: Phase I study of ispenisib (SB-715922) in combination with docetaxel in patients with advanced solid tumours. Proc. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics (2005) 218:C80.
191. JONES SF, PLUMMER ER, BURRIS HA et al.: Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):2027.
192. EI-KHOUEIRY AB, IQBAL DA, SINGH DA et al.: A randomized Phase II non-comparative study of Ispinesib given weekly or every three weeks in metastatic colorectal cancer. A California Cancer Consortium Study (CCC-P). J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):3595.
193. MILLER K, NG C, ANG P et al.: Phase II, open label study of SB-715992 (ispinesib) in subjects with advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium (2005) Abstract 1089.
194. HOLEN KD, BELANI CP, WILDING G et al.: Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):2000.
195. STEIN MN, RUBIN EH, SCOTT PD et al.: Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in cancer patients. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. (2006) 24(18 Suppl.):2001.
196. NIIDA H, NAKANISHI M: DNA damage checkpoints in mammals. Mutagenesis (2006) 21:3-9.
197. CHEN Y, SANCHEZ Y: Chk1 in the DNA damage response: conserved roles from yeasts to mammals. DNA Repair (Amsterdam) (2004) 3:1025-1032.
198. LORD CJ, GARRETT MD, ASHWORTH A: Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin. Cancer Res. (2006) 12:4463-4468.
199. ZHOU BB, BARTEK J: Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat. Rev. Cancer (2004) 4:216-225.
200. XIAO Z, XUE J, SEMIZAROV D et al.: Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics. Int. J. Cancer (2005) 115:528-538.
201. XIAO Z, XUE J, SOWIN TJ et al.: A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene (2005) 24:1403-1411.
202. COLLINS I, GARRETT MD: Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr. Opin. Pharmacol. (2005) 5:366-373.
203. MCARTHUR GA, RALEIGH J, BLASINA A et al.: Imaging with FLT-PET demonstrates that PF-477736, an inhibitor of Chk1 kinase, overcomes a cell cycle checkpoint induced by gemcitabine in PC-3 xenografts. Journal of Clinical Oncology, (2006) ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement), (2006) 3045.
204. GARBER K: New checkpoint blockers begin human trials. Journal of the National Cancer Institute, Vol. 97, No. 14, July 20, (2005) 1026-1028.
205. O'CONNELL MJ, KRIEN MJ, HUNTER T: Never say never. The NIMA-related protein kinases in mitotic control. Trends Cell Biol. (2003) 13:221-228.
206. OSMANI AH, MCGUIRE SL, OSMANI SA: Parallel activation of the NIMA and p34cdc2 cell cycle-regulated protein kinases is required to initiate mitosis in A. nidulans. Cell (1991) 67:283-291.
207. BOWERS AJ, BOYLAN JF: Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors. Gene (2004) 328:135-142.
208. SCHWARTZ GK, SHAH MA: Targeting the cell cycle: a new approach to cancer therapy. J. Clin. Oncol. (2005) 23:9408-9421.
209. BERTHET C, ALEEM E, COPPOLA V et al.: Cdk2 knockout mice are viable. Curr. Biol. (2003) 13:1775-1785.
210. MARTIN A, ODAJIMA J, HUNT SL et al.: Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell. (2005) 7:591-598.
211. KIM DM, KOO SY, JEON K et al.: Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-α or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res. (2003) 63:621-626.
212. DAI Y, RAHMANI M, GRANT S: Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene (2003) 22:7108-7122.
213. SENDEROWICZ AM: Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr. Opin. Cell Biol. (2004) 16:670-678.
214. RICHON VM, SANDHOFF TW, RIFKIND RA, MARKS PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci USA (2000) 97:10014-10019.
215. ARLANDER SJ, EAPEN AK, VROMAN BT et al.: Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J. Biol. Chem. (2003) 278:52572-52577.
216. VASSILEV LT, VU BT, GRAVES B et al.: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 303:844-848.
217. CHANG JC, WOOTEN EC, TSIMELZON A et al.: Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J. Clin. Oncol. (2005) 23:1169-1177.